Connect with us

NEWS

Rudy Giuliani Now Wants To Be Trump’s ‘Personal Science Adviser’

After fading into irrelevancy once the Russia investigation and impeachment wrapped up, former New York City Mayor Rudy Giuliani is making headlines again after lobbying President Donald Trump on untested coronavirus treatments, according to a new report from The Washington Post.

Giuliani, 75, has served as Trump’s personal attorney on a pro bono basis throughout the first term thus far, most often dispatched to defend the president on television amid a mount of scandals.

Now, the former New York Mayor is joining a growing number of Trump confidants pushing Hydroxychloroquine, which The Post reports is “worrying health experts who fear such comments undermine efforts to slow the virus’s spread and downplay the risks of the unproven treatments.

As the Post put it, the former mayor is attempting to position himself as “personal science adviser” to the president.

Last week, Giuliani had a tweet removed for violating Twitter’s misinformation policy when he promoted the anti-malaria drug.

Two weeks ago in Nevada, a man died from trying to immunize himself from the coronavirus with the drug by ingesting fish tank cleaner containing Chloroquine. His wife later said she and her husband thought it was safe because “Trump kept saying it was basically pretty much a cure.”

The former mayor told The Post he has spoken to Trump about the potential treatment “three or four times,” and has sought medical advice from a controversial Long Island doctor with a conservative following and a pharmacist who previously pleaded guilty for conspiring to extort Steven Seagal.

Andrew Kirtzman, Giuliani’s biographer who is working on a second book on the principal, contextualized Rudy’s resurgence in an interview with The Post.

“​He’s been out of the news and out of the limelight since the end of the impeachment drama,” Kirtzman said. “What you’re seeing is an effort to regain relevance.”


Don't miss the latest Political Digs. Sign up for our daily email:


Click to comment
Advertisement
Advertisement

More in NEWS